3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
Etoposide
156
Carboplatin
146
Cisplatin
106
Topotecan
76
durvalumab
52
atezolizumab
51
Irinotecan
45
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
31
PM 01183
25
Drug Therapy
24
anlotinib
23
Gemcitabine
21
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Magnetic Resonance Spectroscopy
13
Bevacizumab
13
rovalpituzumab tesirine
11
amrubicin
11
Specimen Handling
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Solutions
×
Thoracic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled